The purpose of this study is to describe the real-world use of Belantamab Mafodotin - blmf (BLENREP) and associated patterns of care, including dosing and dose modification, eye care specialist visits, associated healthcare utilization, and clinical outcomes in patients with relapsed and/or refractory multiple myeloma (RRMM) seen in the Duke Cancer Institute (DCI) clinics.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Treatment Characteristics: Duration of Treatment With BLENREP
Timeframe: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
Treatment Characteristics: Discontinuation of BLENREP Treatment
Timeframe: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
Treatment Characteristics: Dosing Patterns - Number of Cycles of Treatment With BLENREP Therapy
Timeframe: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
Treatment Characteristics: Dosing Patterns - Delays in Treatment With BLENREP Therapy
Timeframe: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
Treatment Characteristics: Dosing Patterns - Dose Reductions During Treatment With BLENREP Therapy
Timeframe: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
Clinical Outcomes: Best Overall Response
Timeframe: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
Clinical Outcomes: Time To Response
Timeframe: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
Clinical Outcomes: Time To Best Response
Timeframe: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
Clinical Outcomes: Duration of Response
Timeframe: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
Clinical Outcomes: Progression-Free Survival (PFS)
Timeframe: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
Clinical Outcomes: Overall Survival (OS)
Timeframe: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.